Abbott Laboratories (NYSE:ABT) price target raised to $82.00 by Royal Bank of Canada

0

Analyst Ratings For Abbott Laboratories (NYSE:ABT)

Today, Royal Bank of Canada raised its price target on Abbott Laboratories (NYSE:ABT) to $82.00 per share.

There are 14 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.

The current consensus rating on Abbott Laboratories (NYSE:ABT) is Buy with a consensus target price of $80.0063 per share, a potential 2.76% upside.

Some recent analyst ratings include

  • 3/14/2019-Abbott Laboratories (NYSE:ABT) had its Buy rating reiterated by Wells Fargo & Co
  • 2/7/2019-Abbott Laboratories (NYSE:ABT) had its Buy ➝ Buy rating reiterated by Bank of America with a $81.00 price target
  • 1/24/2019-Abbott Laboratories (NYSE:ABT) had its Hold rating reiterated by BTIG Research
  • 1/2/2019-Abbott Laboratories (NYSE:ABT) had its Buy rating reiterated by Gabelli
  • On 3/20/2019 Joseph J Manning, Insider, sold 5,613 with an average share price of $79.58 per share and the total transaction amounting to $446,682.54.
  • On 3/18/2019 Miles D White, Chairman, sold 75,739 with an average share price of $78.61 per share and the total transaction amounting to $5,953,842.79.
  • On 3/13/2019 Roger Bird, Insider, sold 9,188 with an average share price of $79.06 per share and the total transaction amounting to $726,403.28.
  • On 3/6/2019 Sharon J Bracken, Insider, sold 5,500 with an average share price of $77.83 per share and the total transaction amounting to $428,065.00.
  • On 3/1/2019 Brian B Yoor, CFO, sold 2,246 with an average share price of $78.00 per share and the total transaction amounting to $175,188.00.
  • On 3/1/2019 Daniel Gesua Sive Salvadori, EVP, sold 1,664 with an average share price of $78.00 per share and the total transaction amounting to $129,792.00.
  • On 3/1/2019 Jared Watkin, SVP, sold 1,391 with an average share price of $78.00 per share and the total transaction amounting to $108,498.00.

About Abbott Laboratories (NYSE:ABT)
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. Its Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; rapid diagnostics systems for infectious diseases; molecular point-of-care care testing for HIV, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The company's Nutritional Products segment provides pediatric and adult nutritional products. Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company also provides glucose and blood glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

Recent Trading Activity for Abbott Laboratories (NYSE:ABT)
Shares of Abbott Laboratories closed the previous trading session at 77,82 −0,19 0,24 % with shares trading hands.